Skip to main content
Premium Trial:

Request an Annual Quote

Acacia Research

Premium
Acacia Research announced this week that its subsidiary, Combimatrix Molecular Diagnostics, has launched the third version of its Constitutional Array Genetic Test (CA1000) after completing clinical validation.
 
The test utilizes the company's Bacterial Artificial Chromosome array, which includes over 200 new, validated probes. Combimatrix acquired the probes through its partnerships with the Center of Applied Genomics in Toronto and the Erasmus University Medical Center in the Netherlands.
 
The CA1000 improves upon the previous version, the CA850, “by virtue of its increased coverage of genomic loci found in disease ‘hotspots’ further enhancing the test's ability to detect and characterize common genetic disorders,” the company said in a statement.

Filed under

The Scan

Tennessee's COVID-19 Sequencing

The Tennessean reports that a state lab there can now run its own genome sequencing analyses of SARS-CoV-2 samples.

Charged with Sanction Violations

A former professor has been charged with exporting genetic sequencing equipment to Iran in violation of US sanctions, the Miami Herald reports.

Prenetics to Go Public Through SPAC

Prenetics, a Hong Kong-based genomic and diagnostic company, is going public through a SPAC merger, according to 360Dx.

Nature Papers Examine Genomes of Centenarians, Transcription-Coupled DNA Repair

In Nature this week: analysis of centenarian genomes uncovers longevity-linked variants, and more.